Heron Therapeutics Crescita futura
Criteri Future verificati 3/6
Si prevede che Heron Therapeutics aumenterà gli utili e i ricavi rispettivamente del 67.9% e 12.5% all'anno, mentre si prevede che l'EPS crescerà del 68.1% all'anno.
Informazioni chiave
67.9%
Tasso di crescita degli utili
68.05%
Tasso di crescita dell'EPS
| Biotechs crescita degli utili | 24.8% |
| Tasso di crescita dei ricavi | 12.5% |
| Rendimento futuro del capitale proprio | n/a |
| Copertura analitica | Low |
| Ultimo aggiornamento | 03 Jun 2026 |
Aggiornamenti recenti sulla crescita futura
Recent updates
Aggiornamento della narrazione • Jun 12
HRTX: Patent Appeal Outcome Will Shape Future Pricing Opportunity
Heron Therapeutics' updated analyst price target has moved down from $4 to $2, as analysts factor in the recent court decision on Cinvanti patents, the potential for generic competition, and reduced assumptions for growth, profitability, and fair value, alongside a higher discount rate and P/E multiple. Analyst Commentary Recent street research around Heron Therapeutics reflects a clear reset in expectations after the court ruling on Cinvanti patents.
Aggiornamento della narrazione • May 29
HRTX: Reaffirmed 2026 Guidance And Execution Focus May Support Future Upside
Analysts have trimmed their price target on Heron Therapeutics by $2 to reflect updated views on discount rates, expected revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent commentary on Heron Therapeutics centers on how updated assumptions for discount rates, revenue trajectories, margins and future P/E multiples feed into valuation.Aggiornamento della narrazione • May 13
HRTX: Revised Profit Outlook And Discount Rate Could Support Future Upside
Analysts have reduced their price target on Heron Therapeutics by $2, citing updated assumptions around fair value, discount rate, revenue growth, profit margins, and future P/E as the main factors behind the adjustment. Analyst Commentary Recent research points to a more cautious stance on valuation for Heron Therapeutics, with the latest $2 reduction in the price target linked to refreshed assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Seeking Alpha • Feb 18
Heron: Near The Bottom Of A Trading Range Despite Positives
Summary HRTX has reported preliminary Q4'25 net revenues, with Zynrelef experiencing a breakout quarter. Aponvie sales are also still growing, with the acute care franchise being able to offset declines in the oncology care franchise. HRTX recently dealt with its 2026 convertible notes, although the company does now have debt maturing in 2030 and 2031. Read the full article on Seeking AlphaArticolo di analisi • Feb 12
Here's Why Heron Therapeutics (NASDAQ:HRTX) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Dec 16
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have had a really impressive month, gaining 27% after a shaky period...Articolo di analisi • Nov 08
Heron Therapeutics, Inc. (NASDAQ:HRTX) Just Reported, And Analysts Assigned A US$4.50 Price Target
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) missed earnings with its latest third-quarter results, disappointing...
Aggiornamento della narrazione • Aug 15
Advanced Non-Opioid Therapies Will Transform The Pain Management Market
With both the discount rate and consensus revenue growth forecasts for Heron Therapeutics remaining stable, the consensus analyst price target has consequently held steady at $4.75 per share. What's in the News Reaffirmed Q1 2025 net revenue guidance of $153.0 million to $163.0 million.Articolo di analisi • May 09
Heron Therapeutics, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Shareholders might have noticed that Heron Therapeutics, Inc. ( NASDAQ:HRTX ) filed its quarterly result this time last...
Nuova narrazione • Apr 29
ZYNRELEF Label Expansion And VAN Launch Will Broaden Medical Access
Expansion of ZYNRELEF labeling and VAN launch enhance market potential, operational efficiency, and revenue growth.Articolo di analisi • Apr 18
Lacklustre Performance Is Driving Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 26% Price Drop
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has softened a substantial 26% over the previous 30 days...Seeking Alpha • Mar 08
Heron Therapeutics: Four Horse Race Of Approved Therapies
Summary Heron Therapeutics' market cap has risen to ~$360 million, trading at ~$2.38, since my last "Hold" rating in November 2024. I will evaluate Heron's investment merits based on its full year and Q4 2024 earnings, reported on February 27, 2025. The analysis includes insights from Heron's earnings press release, conference call, 10-Q, and presentation. Heron has demonstrated a variety of successful outcomes, warranting a reassessment of its investment potential. Read the full article on Seeking AlphaArticolo di analisi • Mar 01
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shares Bounce 48% But Its Business Still Trails The Industry
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...Articolo di analisi • Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge
The Heron Therapeutics, Inc. ( NASDAQ:HRTX ) share price has fared very poorly over the last month, falling by a...Articolo di analisi • Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders that were waiting for something to happen have been dealt a blow...Articolo di analisi • May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Apr 16
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Summary HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures. The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth. The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion. Read the full article on Seeking AlphaArticolo di analisi • Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) investors will be delighted, with the company turning in some strong numbers...Articolo di analisi • Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have continued their recent momentum with a 27% gain in the last month...Articolo di analisi • Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Despite an already strong run, Heron Therapeutics, Inc. ( NASDAQ:HRTX ) shares have been powering on, with a gain of...Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Utili | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2028 | 202 | 17 | N/A | 36 | 2 |
| 12/31/2027 | 176 | -2 | N/A | 28 | 2 |
| 12/31/2026 | 166 | -12 | N/A | 22 | 2 |
| 3/31/2026 | 151 | -31 | -21 | -20 | N/A |
| 12/31/2025 | 155 | -20 | -28 | -28 | N/A |
| 9/30/2025 | 155 | -14 | -31 | -30 | N/A |
| 6/30/2025 | 150 | -1 | -30 | -28 | N/A |
| 3/31/2025 | 149 | -8 | -24 | -22 | N/A |
| 12/31/2024 | 144 | -14 | -24 | -23 | N/A |
| 9/30/2024 | 138 | -28 | -10 | -8 | N/A |
| 6/30/2024 | 136 | -48 | -23 | -21 | N/A |
| 3/31/2024 | 132 | -81 | -45 | -43 | N/A |
| 12/31/2023 | 127 | -111 | -60 | -59 | N/A |
| 9/30/2023 | 123 | -120 | -100 | -99 | N/A |
| 6/30/2023 | 118 | -137 | -128 | -127 | N/A |
| 3/31/2023 | 114 | -151 | -129 | -128 | N/A |
| 12/31/2022 | 108 | -182 | -149 | -147 | N/A |
| 9/30/2022 | 98 | -217 | -156 | -155 | N/A |
| 6/30/2022 | 95 | -227 | -174 | -171 | N/A |
| 3/31/2022 | 90 | -232 | -209 | -205 | N/A |
| 12/31/2021 | 86 | -221 | -206 | -203 | N/A |
| 9/30/2021 | 86 | -228 | -216 | -211 | N/A |
| 6/30/2021 | 83 | -234 | -204 | -200 | N/A |
| 3/31/2021 | 83 | -228 | -198 | -194 | N/A |
| 12/31/2020 | 89 | -227 | -192 | -185 | N/A |
| 9/30/2020 | 103 | -223 | -167 | -159 | N/A |
| 6/30/2020 | 126 | -198 | -149 | -143 | N/A |
| 3/31/2020 | 140 | -193 | -116 | -108 | N/A |
| 12/31/2019 | 146 | -205 | N/A | -125 | N/A |
| 9/30/2019 | 140 | -196 | N/A | -131 | N/A |
| 6/30/2019 | 117 | -201 | N/A | -141 | N/A |
| 3/31/2019 | 98 | -190 | N/A | -179 | N/A |
| 12/31/2018 | 77 | -179 | N/A | -192 | N/A |
| 9/30/2018 | 59 | -192 | N/A | -205 | N/A |
| 6/30/2018 | 47 | -195 | N/A | -210 | N/A |
| 3/31/2018 | 39 | -199 | N/A | -181 | N/A |
| 12/31/2017 | 31 | -197 | N/A | -170 | N/A |
| 9/30/2017 | 22 | -183 | N/A | -162 | N/A |
| 6/30/2017 | 13 | -190 | N/A | -157 | N/A |
| 3/31/2017 | 5 | -190 | N/A | -152 | N/A |
| 12/31/2016 | 1 | -173 | N/A | -134 | N/A |
| 9/30/2016 | N/A | -156 | N/A | -119 | N/A |
| 6/30/2016 | N/A | -131 | N/A | -102 | N/A |
| 3/31/2016 | N/A | -110 | N/A | -91 | N/A |
| 12/31/2015 | N/A | -98 | N/A | -79 | N/A |
| 9/30/2015 | N/A | -87 | N/A | -68 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Si prevede che HRTX diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 3.5% ).
Guadagni vs Mercato: Si prevede che HRTX diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.
Guadagni ad alta crescita: Si prevede HRTX diventerà redditizia nei prossimi 3 anni.
Ricavi vs Mercato: Si prevede che il fatturato di HRTX ( 12.5% all'anno) crescerà più lentamente rispetto al mercato US ( 12.7% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di HRTX ( 12.5% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Dati insufficienti per determinare se il Return on Equity di HRTX è previsto essere elevato tra 3 anni
Scoprire le aziende in crescita
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/06/14 20:21 |
| Prezzo dell'azione a fine giornata | 2026/06/12 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Heron Therapeutics, Inc. è coperta da 16 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Liisa Bayko | Citizens JMP Securities, LLC |
| Joshua Schimmer | Evercore ISI |